Advancing the understanding of age-specific phenotypes in childhood-onset takayasu arteritis

Khaled Saad1, Soha A Hussain2, Ahmad Roshdy Ahmad3

  • 1Department of Pediatrics, Assiut University, Assiut, Egypt. Khaled.ali@med.au.edu.eg.

Pediatric Research
|November 19, 2025
PubMed

Insights

Childhood-onset Takayasu arteritis (cTAK) presents differently in children of various ages. Tailoring diagnosis and treatment to specific developmental stages is crucial for better outcomes in this rare pediatric vasculitis.

Area of Science:

  • Pediatric rheumatology
  • Vascular biology
  • Developmental biology

Background:

  • Childhood-onset Takayasu arteritis (cTAK) is a rare inflammatory condition affecting large arteries.
  • Existing knowledge often overlooks the significant impact of developmental stages on cTAK presentation and progression.

Purpose of the Study:

  • To characterize age-specific clinical and vascular phenotypes in childhood-onset Takayasu arteritis.
  • To propose a framework for age-tailored diagnostic and therapeutic strategies in cTAK.
  • To introduce the concept of 'developmental vasculopathy' to explain cTAK manifestations.

Main Methods:

  • Retrospective analysis of cTAK patient data stratified by developmental stages (infants, children, adolescents).
  • Correlation of clinical symptoms, imaging findings, and treatment responses with age-specific arterial wall maturation.
  • Comparative analysis with incomplete Kawasaki disease to refine diagnostic criteria.

Main Results:

  • cTAK exhibits distinct clinical and vascular phenotypes that vary significantly across infant, child, and adolescent stages.
  • Specific patterns of arterial wall involvement correlate with developmental maturation, termed 'developmental vasculopathy'.
  • Diagnostic challenges in differentiating cTAK from incomplete Kawasaki disease are highlighted, particularly in younger age groups.

Conclusions:

  • Childhood-onset Takayasu arteritis is not a monolithic disease; age-specific phenotypes necessitate tailored approaches.
  • Implementing age-stratified diagnostic and management strategies, guided by 'developmental vasculopathy', can improve patient outcomes.
  • Personalized medicine, including precision diagnostics and targeted interventions, represents a new era for managing cTAK in children.
Abstract

Related Concept Videos

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
444
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
460
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
835
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
415
Pulmonary Hypertension: Classification and Pathogenesis01:30

Pulmonary Hypertension: Classification and Pathogenesis

Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
547
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301